Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Company Drug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

Fineline Cube Nov 1, 2024

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...

Company Deals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Fineline Cube Nov 1, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...

Company Drug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Fineline Cube Nov 1, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...

Company Drug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Fineline Cube Nov 1, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...

Company Drug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

Fineline Cube Nov 1, 2024

China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment

Fineline Cube Oct 31, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...

Company

Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales

Fineline Cube Oct 31, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...

Company

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase

Fineline Cube Oct 31, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...

Company Deals

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments

Fineline Cube Oct 31, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...

Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Fineline Cube Oct 31, 2024

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...

Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Fineline Cube Oct 31, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...

Company Deals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Fineline Cube Oct 31, 2024

China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...

Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound

Fineline Cube Oct 31, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...

Company

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes

Fineline Cube Oct 31, 2024

Leon Wang, Executive Vice President International and AstraZeneca (AZ, NASDAQ: AZN) China President, is cooperating...

Company Drug

AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Fineline Cube Oct 31, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...

Company Deals Medical Device

Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access

Fineline Cube Oct 31, 2024

Jiangsu Yuyue Medical Equipment Inc., (SHE: 002223), a Chinese medical equipment manufacturer, has entered into...

Company

GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth

Fineline Cube Oct 31, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia

Fineline Cube Oct 31, 2024

China-based Allmed Medical Products Co., Ltd (SHE: 002950) has announced plans to establish a wholly...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Files for New Indication with China’s NMPA

Fineline Cube Oct 31, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that the National Medical Products Administration...

Posts pagination

1 … 301 302 303 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.